Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

被引：87
|
作者：
Choi, Michael Y. [1 ]
Widhof, George F., II [1 ]
Wu, Christina C. N. [1 ]
Cui, Bing [1 ]
Lao, Fitzgerald [1 ]
Sadarangani, Anil [1 ,2 ]
Cavagnaro, Joy [3 ]
Prussak, Charles [1 ]
Carson, Dennis A. [1 ]
Jamieson, Catriona [1 ,2 ]
Kipps, Thomas J. [1 ]
机构：
[1] Univ Calif San Diego, Dept Med, Div Hematol Oncol, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Div Regenerat Med, La Jolla, CA 92093 USA
[3] Access Bio, Boyce, VA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2015年 / 15卷
基金：
美国国家卫生研究院;
关键词：
AKT; cancer stem cell; Cirmtuzumab; CLL; Wnt receptor; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIGEN ROR1; EXPRESSION; RECEPTOR; PSEUDOKINASE; PHENOTYPE; FAMILY; CLL;
D O I：
10.1016/j.clml.2015.02.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL. (C) 2015 The Authors. Published by Elsevier Inc.
引用
收藏
页码：S167 / S169
页数：3
相关论文
共 50 条
  • [21] BBT-401 IS A SELECTIVE PELLINO-1 PROTEIN-PROTEIN INTERACTION INHIBITOR IN CLINICAL DEVELOPMENT TARGETING A FIRST-IN-CLASS DRUG FOR UC TREATMENT
    Lee, Gwanghee
    Lee, YounSook
    Chang, Mikyoung
    Kang, Sang U. K.
    Ryou, Jeong-Hyun
    Lim, Jong-Jin
    Imran, Ali
    Park, Seok-Hee
    Lee, Kwangho
    Lee, Yong-Hee
    GASTROENTEROLOGY, 2019, 156 (03) : S82 - S82
  • [22] First-in-Class Oral Small Molecule Against the Tyrosine Kinase ROR1 (KAN0439834) Induced Significant Apoptosis of Chronic Lymphocytic Leukemia Cells
    Hojjat-Farsangi, Mohammad
    Daneshmanesh, Amir Hossein
    Mozaffari, Fariba
    Hansson, Lotta
    Vagberg, Jan
    Bystrom, Styrbjorn
    Olsson, Elisabeth
    Lofberg, Charlotta
    Norstrom, Charlotta Carina
    Schultz, Johan
    Norin, Martin
    Olin, Thomas
    Osterborg, Anders
    Moshfegh, Ali
    Mellstedt, Hakan
    BLOOD, 2017, 130
  • [23] Radiolabeling and pre-clinical evaluation of a first-in-class CD19 PET Tracer for imaging B cells in multiple sclerosis
    Stevens, Marc
    Cropper, Haley
    Jackson, Isaac
    Chaney, Aisling
    Lechtenberg, Kendra
    Buckwalter, Marion
    James, Michelle L.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [24] Safety, tolerability, and preliminary efficacy of nadunolimab, a first-in-class monoclonal antibody against IL1RAP, in combination with pembrolizumab in subjects with solid tumors
    Jauhari, Shekeab
    Jimeno, Antonio
    Hreno, Jennifer
    Bauml, Joshua Michael
    Garcia-Ribas, Ignacio
    Ohman, Marie Wallen
    Rydberg-Millrud, Camilla
    Cohen, Roger B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] BSI-507, a first-in-class bispecific antibody targeting PD1 and PVRIG for cancer immunotherapy
    Peng, Zeyu
    Liu, Xiaodong F.
    Li, Hongyan
    Dai, Wenwen
    Liu, Jinyu
    Hao, Xiaoyao
    Xia, Shukai
    Lv, Qun
    Davis, Hugh M.
    Chen, Mingjiu
    Ma, Mark Z.
    CANCER RESEARCH, 2023, 83 (07)
  • [26] APhase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers
    Lassen, Ulrik N.
    Meulendijks, Didier
    Siu, Lilian L.
    Karanikas, Vaios
    Mau-Sorensen, Morten
    Schellens, Jan H. M.
    Jonker, Derek J.
    Hansen, Aaron R.
    Simcox, Mary E.
    Schostack, Kathleen J.
    Bottino, Dean
    Zhong, Hua
    Roessler, Markus
    Vega-Harring, Suzana M.
    Jarutat, Tiantom
    Geho, David
    Wang, Ka
    DeMario, Mark
    Goss, Glenwood D.
    CLINICAL CANCER RESEARCH, 2015, 21 (02) : 258 - 266
  • [27] BBT-401 IS A SELECTIVE PELLINO-1 PROTEIN-PROTEIN INTERACTION INHIBITOR IN CLINICAL DEVELOPMENT TARGETING A FIRST-IN-CLASS DRUG FOR UC TREATMENT.
    Lee, Gwanghee
    Lee, YounSook
    Chang, Mikyoung
    Kang, Sang Uk
    Ryou, Jeong-Hyun
    Lim, Jong-Jin
    Imran, Ali
    Park, Seok-Hee
    Lee, Kwangho
    Lee, Yong-Hee
    INFLAMMATORY BOWEL DISEASES, 2019, 25 : S58 - S58
  • [28] The first-in-class BMI-1 modulators PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma
    Bolomsky, Arnold
    Muller, Josephine
    Lejeune, Margaux
    Arnold, Dominik
    Duray, Elodie
    Breid, Helene
    Vrancken, Louise
    Hubl, Wolfgang
    Zojer, Niklas
    Caers, Jo
    Ludwig, Heinz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E113 - E114
  • [29] Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas.
    Schuler, Martin H.
    Zvirbule, Zanete
    Lordick, Florian
    Krilova, Anna
    Helbig, Ulrike
    Schulze-Bergkamen, Henning
    Thuss-Patience, Peter C.
    von Wichert, Goetz
    Schulmann, Karsten
    Trarbach, Tanja
    Bauer, Stefan
    Mueller, Christian
    Al-Batran, Salah-Eddin
    Huber, Christoph
    Sahin, Ugur
    Tureci, Oezlem
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Characterization of the anticancer and immunologic activity of RGX-019, a novel pre-clinical stage humanized monoclonal antibody targeting the MERTK receptor
    Takeda, Shugaku
    Andreu-Agullo, Celia
    Sridhar, Subhasree
    Halberg, Nils
    Lorenz, Ivo C.
    Tavazoie, Sohail
    Kurth, Isabel
    Tavazoie, Masoud
    CANCER RESEARCH, 2019, 79 (13)
12345